Bringing an orphan drug to market in Europe has never been more challenging. Stricter regulations, increasing scrutiny on drug pricing and growing influence from patient advocacy groups are reshaping the landscape.
Securing reimbursement and market access now requires earlier engagement with stakeholders, a patient-centric approach, and a deep understanding of evolving pricing policies. Without the right strategy, companies risk delays, restricted access or commercial failure.
This webinar will equip you with expert insights on patient engagement, pricing and reimbursement and regulatory navigation, helping build a launch strategy that drives access, adoption and long-term success in 2025 and beyond.
The expert speakers reveal the essential strategies for overcoming these challenges and securing a successful launch:
- Highlighting why early patient engagement is critical not just for regulatory approval, but for building trust and ensuring long-term adoption
- Latest trends in European market access, pricing and reimbursement, providing strategies to stay ahead in a rapidly evolving landscape
- Providing a patient advocacy perspective, illustrating how industry collaboration can unlock new market access opportunities
If involved in orphan drug development, the attendees will gain practical, expert-backed strategies to avoid costly pitfalls, accelerate access and maximize launch success in 2025.
Register for this webinar today to optimize pricing and reimbursement strategies and leverage patient advocacy for a successful market launch of orphan drugs.
Speakers
![Dr. Raymond A. Huml, Sciensus](https://i0.wp.com/xtalks.com/wp-content/uploads/2025/02/Ray-150.jpg?fit=150%2C150&ssl=1)
Dr. Raymond A. Huml, Vice President of Rare Strategy, Sciensus
Dr. Raymond A. Huml, MS, DVM, RAC, is Vice President of Rare & Orphan Disease Strategy at Sciensus, with over 30 years in the healthcare and biopharmaceutical industries. A leader in rare disease research and global due diligence, he has driven nearly $3 billion in capital commitments.
A prolific author and award-winning expert, he is dedicated to advancing rare disease innovation, diversity, and global healthcare, including his Peace Corps service in Ghana.
![Andrew Cummins, Sciensus](https://i0.wp.com/xtalks.com/wp-content/uploads/2025/02/Andrew-150.jpg?fit=150%2C150&ssl=1)
Andrew Cummins, Vice President of Business Development, Sciensus
Andrew Cummins leads business development at Sciensus, pioneering access strategies for rare disease therapies. With expertise in health technology appraisal, patient support and real-world data, he ensures innovative services align with pharma and biotech needs. Under his leadership, Sciensus expands treatment accessibility from early trials to full market integration.
Passionate about patient outcomes, he fosters key relationships and solves industry challenges with creativity and precision. His success in navigating product lifecycles across global markets reflects a deep understanding of market dynamics and a commitment to innovation in rare disease management.
![Kirsty Hoyle, Metabolic Support UK](https://i0.wp.com/xtalks.com/wp-content/uploads/2025/02/Kirsty-Hoyle-150.jpg?fit=150%2C150&ssl=1)
Kirsty Hoyle, CEO, Metabolic Support UK
Kirsty Hoyle is the CEO of Metabolic Support UK, driving innovation in healthcare advocacy, technology and policy for those with rare diseases. With over a decade of dedication, she has held impactful roles, including at Transport for All, championing accessibility and equal opportunities.
Who Should Attend?
This webinar will appeal to:
- Market Access and Pricing Specialists
- Regulatory affairs professionals
- Commercial and Business Strategy Executives
- Patient Advocacy and Engagement Leads
- Medical affairs
- Pharmaceutical and Biotech Industry Leaders
What You Will Learn
Attendees will learn about:
- The importance of early patient engagement in shaping access strategies
- Key market access, pricing and reimbursement challenges in Europe
- Effective approaches to navigating regulatory and commercialisation hurdles
- How patient advocacy partnerships can enhance launch success
Xtalks Partner
Sciensus
Sciensus is a leading European life sciences organisation with over 30 years of experience. We’re redefining patient-centric care, connecting patients with life-changing medicines while empowering pharmaceutical companies and healthcare professionals with the insights needed to improve people’s lives.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account